Add to ORKGSerotonergic neurons play an important role in modulating extrapyramidal motor disorders such as Parkinson’s disease and drug-induced parkinsonism. Here we reviewed the actions of 5-HT 1A agonists in animal models of extrapyramidal symptoms (EPS) and discussed their therapeutic potential in treating EPS. 5-HT 1A agonists (e.g., 8-hydroxy-2-(di-n-propylamino)tertraline and tandospirone) significantly improved various types of EPS including antipsychotic-induced bradykinesia and catalepsy, and dopaminergic neurotoxin-induced bradykinesia. The antiparkinsonian action of 5-HT 1A agonists was blocked by 5-H
An increasing body of experimental evidence suggests that serotonergic neurons play a major role in ...
Several studies support the hypothesis of 5-HT (serotonin) involvement in the physiopathology of the...
Recently, the biased and highly selective 5-HT1A agonists, NLX-112, F13714 and F15599, have been sho...
5-HT(1) receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat...
Appearance of dyskinesia represents the most problematic side effect during chronic L-DOPA treatment...
5-HT plays a regulatory role in voluntary movements of the basal ganglia and have a major impact on ...
Background and the purpose of the study: In Parkinson›s disease (PD) prolong use of L-DOPA causes s...
5-HT1 receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat a...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
L-DOPA therapy in Parkinson’s disease (PD) is limited due to emerging L-DOPA-induced dyskinesia. Res...
AbstractIntroductionThe serotonin (5-HT) syndrome (SS) in man covers side effects of drugs in over d...
5-HT2A/2C receptors are one of the most important in controlling basal ganglia outputs. In rodent mo...
L-DOPA is the gold-standard treatment for Parkinson's disease (PD), but induces troublesome dyskines...
An increasing body of experimental evidence suggests that serotonergic neurons play a major role in ...
Several studies support the hypothesis of 5-HT (serotonin) involvement in the physiopathology of the...
Recently, the biased and highly selective 5-HT1A agonists, NLX-112, F13714 and F15599, have been sho...
5-HT(1) receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat...
Appearance of dyskinesia represents the most problematic side effect during chronic L-DOPA treatment...
5-HT plays a regulatory role in voluntary movements of the basal ganglia and have a major impact on ...
Background and the purpose of the study: In Parkinson›s disease (PD) prolong use of L-DOPA causes s...
5-HT1 receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat a...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's disease pa...
L-DOPA therapy in Parkinson’s disease (PD) is limited due to emerging L-DOPA-induced dyskinesia. Res...
AbstractIntroductionThe serotonin (5-HT) syndrome (SS) in man covers side effects of drugs in over d...
5-HT2A/2C receptors are one of the most important in controlling basal ganglia outputs. In rodent mo...
L-DOPA is the gold-standard treatment for Parkinson's disease (PD), but induces troublesome dyskines...
An increasing body of experimental evidence suggests that serotonergic neurons play a major role in ...
Several studies support the hypothesis of 5-HT (serotonin) involvement in the physiopathology of the...
Recently, the biased and highly selective 5-HT1A agonists, NLX-112, F13714 and F15599, have been sho...